The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency respond to selected treatments.
A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency.
|Eligibility criteria|| |
Participation is based on a mutation found in screening blood test and tumour tissue result.
|Study details|| |
If you have the mutation required for the study in either your blood or tumour tissue you will be further screened for the study. The study is a randomised treatment with the ratio 2:1, if you receive the standard of care treatment, your doctor will choose this for you. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW